RealTime Dynamix™: Rheumatoid Arthritis US Q2 2018 Spotlight
After a year on the market, Sanofi / Regeneron’s Kevzara has had little success overthrowing Roche/Genentech’s Actemra as the go-to IL-6 inhibitor for treating rheumatoid arthritis (RA), as less than half of US rheumatologists (n=100) have experience prescribing the drug to their RA patients. If Olumiant does not bring a clear differentiator, it could follow suit. The below complimentary highlights are taken from the Q2 2018 wave of RealTime Dynamix: Rheumatoid Arthritis US.
Contact [email protected] for more information about the highlighted reports or to see if your company already has access to the US or EU report series.
All company, brand or product names and logos in this document are trademarks of their respective holders.